Common Contracts
5 similar Employment Agreement contracts by Acceleron Pharma Inc
AMENDMENT TO THE EMPLOYMENT AGREEMENTEmployment Agreement • November 4th, 2021 • Acceleron Pharma Inc • Biological products, (no disgnostic substances)
This Amendment (“Amendment”), effective as of September 29, 2021, by and between Acceleron Pharma Inc., a Delaware corporation (“Acceleron”), and Kevin McLaughlin, SVP, Chief Financial Officer (the “Executive”), amends that certain Employment Agreement between Executive and Acceleron, dated as of February 13, 2014, as amended (“Agreement”). Together Acceleron and Executive are the “Parties” and each is a “Party”.
AMENDMENT TO THE EMPLOYMENT AGREEMENTEmployment Agreement • November 4th, 2021 • Acceleron Pharma Inc • Biological products, (no disgnostic substances) • Delaware
This Amendment (“Amendment”), effective as of September 29, 2021, by and between Acceleron Pharma Inc., a Delaware corporation (“Acceleron”), and Jay Backstrom, EVP, Research and Development (the “Executive”), amends that certain Employment Agreement between Executive and Acceleron, dated as of December 10, 2019 (“Agreement”). Together Acceleron and Executive are the “Parties” and each is a “Party”.
AMENDMENT TO THE EMPLOYMENT AGREEMENTEmployment Agreement • November 4th, 2021 • Acceleron Pharma Inc • Biological products, (no disgnostic substances) • Delaware
This Amendment (“Amendment”), effective as of September 29, 2021, by and between Acceleron Pharma Inc., a Delaware corporation (“Acceleron”), and Sujay Kango, EVP, Chief Commercial Officer (the “Executive”), amends that certain Employment Agreement between Executive and Acceleron, dated as of February 12, 2018 (“Agreement”). Together Acceleron and Executive are the “Parties” and each is a “Party”.
AMENDMENT TO THE EMPLOYMENT AGREEMENTEmployment Agreement • November 4th, 2021 • Acceleron Pharma Inc • Biological products, (no disgnostic substances) • Delaware
This Amendment (“Amendment”), effective as of September 29, 2021, by and between Acceleron Pharma Inc., a Delaware corporation (“Acceleron”), and Adam Veness, SVP, General Counsel (the “Executive”), amends that certain Amended and Restated Employment Agreement between Executive and Acceleron, dated as of June 5, 2019 (“Agreement”). Together Acceleron and Executive are the “Parties” and each is a “Party”.
AMENDMENT TO THE EMPLOYMENT AGREEMENTEmployment Agreement • November 4th, 2021 • Acceleron Pharma Inc • Biological products, (no disgnostic substances)
This Amendment (“Amendment”), effective as of September 29, 2021, by and between Acceleron Pharma Inc., a Delaware corporation (“Acceleron”), and Habib Dable, President and Chief Executive Officer (the “Executive”), amends that certain Employment Agreement between Executive and Acceleron, dated as of September 23, 2016 (“Agreement”). Together Acceleron and Executive are the “Parties” and each is a “Party”.
